Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Cash Flows From Operating Activities:
Net loss	$ (2,478,912)	$ (9,793,431)	$ (6,871,406)
Adjustments to reconcile net loss to cash used in operating activities
Change in fair value of warrant liability	(1,599,623)	(3,845,514)	(7,077,376)
Change in fair value of investment option liability	(1,809,622)	(1,809,622)
Change in fair value of derivative liability	231,000	284,000
Stock-based compensation		2,091,299	4,829,484
Inducement expense			298,714
Amortization of right-of-use asset		103,365
Amortization of intangible assets	42,187	126,563	482,115
Depreciation expense	44,458	114,850	2,240
Change in operating assets and liabilities:
Prepaid expenses and other current assets		(758,419)	320,123
Accounts payable and accrued liabilities		(106,675)	625,748
Right-of-use operating lease liability		(91,022)
Net cash used in operating activities		(13,684,606)	(7,390,358)
Cash Flows From Investing Activities:
Purchases of property and equipment		(577,972)
Purchase of Diverse Bio license agreement			(675,000)
Cash accretive acquisition of MagicMed			3,055,327
Net cash (used in) provided by investing activities		(577,972)	2,380,327
Cash Flows From Financing Activities:
Proceeds from sale of common stock, warrants, and investment options, net of offering costs		17,222,100	21,614,488
Proceeds from the sale of redeemable non-controlling interest, net of offering costs (see Note 6)		958,038
Proceeds from warrant exercises, net of fees			3,285,164
Net cash provided by financing activities		18,180,138	24,899,652
Effect of foreign exchange rate on cash		(72,554)	(19,655)
Net increase in cash		3,845,006	19,869,966
Cash at beginning of period		17,355,999	1,578,460
Cash at end of period	21,201,005	21,201,005	21,448,426
Supplemental disclosure of cash and non-cash transactions:
Cash paid for interest		5,114	5,191
Income taxes paid
Investment options issued in conjunction with common stock issuance		4,323,734
Modification of warrants as part of share capital raise		251,357
Warrants issued in conjunction with common stock issuance		3,595,420
Issuance of embedded derivative		402,000
Preferred dividends attributable to redeemable non-controlling interest	(12,603)	20,411
Accretion of embedded derivative to redemption value	$ (110,991)	184,985
Issuance of Common Stock pursuant to MagicMed amalgamation			39,042,282
Deferred tax liability incurred due to MagicMed amalgamation			9,061,927
Conversion of preferred stock to common stock			32,754
Fair value of warrants issued			9,981,000
Fair value of Ameri warrants			$ 262,492